MMAI alone does not appear to produceserotonergic neurotoxicity with either acute or chronic administration in animals.[8][9] However, subsequent research found that a single high dose of MMAI could produce significant serotonergic neurotoxicity.[8][9] In addition, combination of MMAI with thedopamine releasing agentdextroamphetamine has been found to producedose-dependent serotonergic neurotoxicity in animals.[8] Hence, MMAI is not a fully non-neurotoxicMDMAanalogue.[8][9]
^Li Q, Murakami I, Stall S, Levy AD, Brownfield MS, Nichols DE, Van de Kar LD (December 1996). "Neuroendocrine pharmacology of three serotonin releasers: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (MBDB), 5-methoxy-6-methyl-2-aminoindan (MMAi) and p-methylthioamphetamine (MTA)".The Journal of Pharmacology and Experimental Therapeutics.279 (3):1261–1267.doi:10.1016/S0022-3565(25)21285-X.PMID8968349.
^Rudin D, Liechti ME, Luethi D (September 2021). "Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics".Exp Neurol.343: 113778.doi:10.1016/j.expneurol.2021.113778.PMID34090893.
^Marona-Lewicka D, Nichols DE (December 1997). "The Effect of Selective Serotonin Releasing Agents in the Chronic Mild Stress Model of Depression in Rats".Stress.2 (2):91–100.doi:10.3109/10253899709014740.PMID9787258.
^Scorza C, Silveira R, Nichols DE, Reyes-Parada M (July 1999). "Effects of 5-HT-releasing agents on the extracellullar hippocampal 5-HT of rats. Implications for the development of novel antidepressants with a short onset of action".Neuropharmacology.38 (7):1055–1061.doi:10.1016/S0028-3908(99)00023-4.PMID10428424.S2CID13714807.
^abcdJohnson MP, Nichols DE (July 1991). "Combined administration of a non-neurotoxic 3,4-methylenedioxymethamphetamine analogue with amphetamine produces serotonin neurotoxicity in rats".Neuropharmacology.30 (7):819–822.doi:10.1016/0028-3908(91)90192-e.PMID1717873.
^abcJohnson MP, Conarty PF, Nichols DE (July 1991). "[3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues".Eur J Pharmacol.200 (1):9–16.doi:10.1016/0014-2999(91)90659-e.PMID1685125.
^Glennon RA, Dukat M (2017). "Structure-Activity Relationships of Synthetic Cathinones".Neuropharmacology of New Psychoactive Substances (NPS). Current Topics in Behavioral Neurosciences. Vol. 32. pp. 19–47.doi:10.1007/7854_2016_41.ISBN978-3-319-52442-9.PMC5818155.PMID27830576.